|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
8 JUNE 2010
|
| |
|
This expert interview with Dean Bajorin, MD, from Memorial Sloan-Kettering Cancer Center in New York, New York, and Lee Lokey, MD, from prIME Oncology in Atlanta, Georgia, discusses the topic of genitourinary malignancies focusing on the following data releases:
#LBA4507: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer
#4508: Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)
#CRA4504: Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633)
#4517: Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004)
|
| |
|
View an expert interview and opinion with Dean Bajorin, MD, and Lee Lokey, MD 
Click here to complete the post-test online |
|
|
|
|
|
|
